{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:07:40Z","timestamp":1790665660621,"version":"4.1.0"},"reference-count":114,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T00:00:00Z","timestamp":1554249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009828","name":"Cancer Research Wales","doi-asserted-by":"publisher","award":["13054"],"award-info":[{"award-number":["13054"]}],"id":[{"id":"10.13039\/100009828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007903","name":"Bloodwise","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007903","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,7]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Chronic lymphocytic leukaemia (<jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>) has long been thought to be an immunosuppressive disease and abnormalities in T\u2010cell subset distribution and function have been observed in many studies. However, the role of T cells (if any) in disease progression remains unclear and has not been directly studied. This has changed with the advent of new therapies, such as chimeric antigen receptor\u2010T cells, which actively use retargeted patient\u2010derived T cells as \u201cliving drugs\u201d for <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content>. However complete responses are relatively low (~26%) and recent studies have suggested the differentiation status of patient T cells before therapy may influence efficacy. Non\u2010chemotherapeutic drugs, such as idelalisib and ibrutinib, also have an impact on T cell populations in <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content> patients. This review will highlight what is known about T cells in <jats:styled-content style=\"fixed-case\">CLL<\/jats:styled-content> during disease progression and after treatment, and discuss the prospects of using T cells as predictive biomarkers for immune status and response to therapy.<\/jats:p>","DOI":"10.1111\/bjh.15918","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T01:04:34Z","timestamp":1554339874000},"page":"220-233","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Chronic lymphocytic leukaemia: the role of T cells in a B cell disease"],"prefix":"10.1111","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9103-1686","authenticated-orcid":false,"given":"Stephen","family":"Man","sequence":"first","affiliation":[{"name":"Section\u00a0of Haematology Division of Cancer and Genetics Cardiff University School of Medicine Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8935-2672","authenticated-orcid":false,"given":"Peter","family":"Henley","sequence":"additional","affiliation":[{"name":"Section\u00a0of Haematology Division of Cancer and Genetics Cardiff University School of Medicine Cardiff UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,4,3]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12401"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-195792"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature13444"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02605.x"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.20643"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.005835"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800570"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-324210"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04444"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0642"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2011.164"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-764712"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.077537"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879429"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1371399"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(74)90944-1"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1981.tb02682.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.0401"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-299321"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006061"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-417519"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1093"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2010.08.010"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05115"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1545-0"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-765685"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1001783"},{"key":"e_1_2_7_31_1","first-page":"1","article-title":"Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide\/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL\u20105 AGMT phase I\/II study","volume":"97","author":"Egle A.","year":"2018","journal-title":"Annals of Hematology"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15802"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3567"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199509059649"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-12-130120"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-679134"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1315226"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0920-3"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2010.503820"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24176"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1473-z"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3639"},{"key":"e_1_2_7_44_1","first-page":"37","article-title":"Control of chronic lymphocytic leukemia development by clonally\u2010expanded CD8+ T\u2010cells that undergo functional exhaustion in secondary lymphoid tissues","volume":"10","author":"Hanna B.S.","year":"2018","journal-title":"Leukemia"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1068308"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-271171"},{"key":"e_1_2_7_47_1","first-page":"157","article-title":"Imbalance of T cell subpopulations in patients with chronic lymphocytic leukaemia of the B cell type","volume":"49","author":"Herrmann F.","year":"1982","journal-title":"Clinical and Experimental Immunology"},{"key":"e_1_2_7_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.111"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0078091"},{"key":"e_1_2_7_50_1","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1182\/blood.V54.2.540.540","article-title":"T\u2010cell subpopulations in chronic lymphocytic leukemia: abnormalities in distribtuion and in in\u00a0vitro receptor maturation","volume":"54","author":"Kay N.E.","year":"1979","journal-title":"Blood"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.4.1165"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1300-y"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.9.5595"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.728287"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-707133"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00455"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2011.03439.x"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI89756"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0182"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830200420"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2017.187070"},{"key":"e_1_2_7_62_1","first-page":"96","article-title":"Kinetics of T\u2010cell subset reconstitution following treatment with bendamustine and rituximab for low\u2010grade lymphoproliferative disease: a population\u2010based analysis","volume":"31","author":"Mart\u00ednez\u2010Calle N.","year":"2018","journal-title":"British Journal of Haematology"},{"key":"e_1_2_7_63_1","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.1182\/blood-2018-99-113134","article-title":"The BCL\u20102\u2010selective inhibitor venetoclax spares activated T\u2010cells during anti\u2010tumor immunity","volume":"132","author":"Mathew R.","year":"2018","journal-title":"Blood"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1981.tb07274.x"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-01-622936"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/0145-2126(82)90081-9"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1002\/cytob.21120"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403907"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2017.07.004"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1965"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-0393"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-2630"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14475"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2013.07.011"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature22991"},{"key":"e_1_2_7_76_1","first-page":"460","article-title":"Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade","volume":"33","author":"Pallasch C.P.","year":"2009","journal-title":"The Lancet"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.151100"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24403"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-108605"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V78.6.1569.1569"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04466.x"},{"key":"e_1_2_7_83_1","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.4049\/jimmunol.129.5.2305","article-title":"Abnormal T lymphocyte subpopulations in patients with B cell chronic lymphocytic leukemia: an analysis by monoclonal antibodies","volume":"129","author":"Platsoucas C.D.","year":"1982","journal-title":"Journal of Immunology"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2249.2001.01639.x"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-257147"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2018.03.002"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-518183"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2008.07.005"},{"key":"e_1_2_7_89_1","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay A.G.","year":"2008","journal-title":"Journal of Clinical Investigation"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457531"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28884"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257"},{"key":"e_1_2_7_93_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-11-0116"},{"key":"e_1_2_7_94_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07363.x"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2008.05.009"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00086"},{"key":"e_1_2_7_97_1","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.4049\/jimmunol.158.3.1482","article-title":"Clonal expansion within the CD4+CD57+ and CD8+CD57+ T cell subsets in chronic lymphocytic leukemia","volume":"158","author":"Serrano D.","year":"1997","journal-title":"Journal of Immunology"},{"key":"e_1_2_7_98_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02882.x"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1101\/sqb.2013.78.022905"},{"key":"e_1_2_7_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-140582"},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318197b5e4"},{"key":"e_1_2_7_102_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.673224"},{"key":"e_1_2_7_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.2.786.786"},{"key":"e_1_2_7_104_1","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.1182\/blood-2018-99-118734","article-title":"Mass cytometry identifies T cell populations associated with severe hepatotoxicity in CLL patients on upfront idelalisib","volume":"132","author":"Vartanov A.R.","year":"2018","journal-title":"Blood"},{"key":"e_1_2_7_105_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-2476"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023698"},{"key":"e_1_2_7_107_1","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1182\/blood-2018-99-116283","article-title":"First evidence of restoration of T and NK cell compartment after venetoclax treatment","volume":"132","author":"Weerdt I.","year":"2018","journal-title":"Blood"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0531-5565(01)00212-1"},{"key":"e_1_2_7_109_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10522-008-9138-6"},{"key":"e_1_2_7_110_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-016-1922-6"},{"key":"e_1_2_7_111_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.082248"},{"key":"e_1_2_7_112_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9941"},{"key":"e_1_2_7_113_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-740993"},{"key":"e_1_2_7_114_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601190"},{"key":"e_1_2_7_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.89"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15918","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjh.15918","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15918","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T21:00:20Z","timestamp":1694379620000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,3]]},"references-count":114,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.1111\/bjh.15918"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15918","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,3]]},"assertion":[{"value":"2019-04-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}